Latest News
  1. Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
  2. Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
  3. KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment

News

Glenmark Launches Lung Cancer Drug Tevimbra in India After Regulatory Approval

This is Glenmark’s first product in the immuno-oncology category, which targets cancer by enhancing the body’s immune response. The company said the launch is part of its strategy to expand its oncology portfolio with innovative treatments.

Glenmark Launches Lung Cancer Drug Tevimbra in India After Regulatory Approval
News

Glenmark Pharmaceuticals on Tuesday announced the launch of Tevimbra, a lung cancer treatment drug, in India following approval from the Central Drugs Standard Control Organisation (CDSCO). The drug, developed by global oncology firm BeiGene (now BeOne Medicines), marks Glenmark’s entry into the immuno-oncology segment in the domestic market.

According to a regulatory filing, this is Glenmark’s first product in the immuno-oncology category, which targets cancer by enhancing the body’s immune response. The company said the launch is part of its strategy to expand its oncology portfolio with innovative treatments.

Alok Malik, President and Business Head of India Formulations at Glenmark, said the company aims to improve access to therapies with established safety and efficacy profiles. He added that the immuno-oncology segment holds potential for treating complex, advanced-stage cancers.

Tevimbra is indicated for the treatment of:

First-line, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy

Second-line monotherapy for locally advanced or metastatic NSCLC

Monotherapy for oesophageal squamous cell carcinoma (ESCC)

The drug is already approved and marketed in several major markets, including the United States, European Union, Australia, and China.

Glenmark Pharmaceuticals reported a consolidated net profit of ₹4.65 crore for the quarter ended March 2025, compared to a net loss of ₹1,218.28 crore in the corresponding quarter of the previous year. Net sales for the quarter rose 6.77% year-on-year to ₹3,220.13 crore.

Shares of Glenmark closed 0.78% higher at ₹1,699.25 on the BSE following the announcement.

Glenmark is a research-led pharmaceutical company with a presence in branded, generic, and over-the-counter segments. Its key therapeutic areas include respiratory, dermatology, and oncology.